Neumora Therapeutics, Inc.
NMRA
$0.7798
$0.01281.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 18.92% | -23.59% | -9.27% | 50.59% | -105.05% |
| Total Depreciation and Amortization | 0.64% | -2.50% | 1.27% | -4.82% | -4.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.15% | -17.00% | 62.68% | -90.01% | 1,019.45% |
| Change in Net Operating Assets | -104.61% | 425.85% | -351.55% | 127.39% | -999.08% |
| Cash from Operations | -50.34% | 40.38% | -30.74% | 16.50% | -7.68% |
| Capital Expenditure | -- | -- | 100.00% | -1,661.36% | -18.92% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -163.43% | 638.59% | 114.24% | -1,187.57% | -42.47% |
| Cash from Investing | -162.93% | 638.59% | 114.17% | -1,196.74% | -42.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 774.03% | -33.84% | 43.85% | 444.25% | -99.86% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 200.00% | -- | -- | -- | 71.35% |
| Cash from Financing | 917.18% | -42.31% | 43.85% | 483.58% | -100.21% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -206.82% | 487.72% | 83.13% | -399.69% | -118.38% |